IFRX vs. AFMD, BRNS, LPTX, VACC, LFVN, BYSI, PRPH, GNLX, ONCY, and CMRX
Should you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Affimed (AFMD), Barinthus Biotherapeutics (BRNS), Leap Therapeutics (LPTX), Vaccitech (VACC), LifeVantage (LFVN), BeyondSpring (BYSI), ProPhase Labs (PRPH), Genelux (GNLX), Oncolytics Biotech (ONCY), and Chimerix (CMRX). These companies are all part of the "pharmaceutical preparations" industry.
InflaRx (NASDAQ:IFRX) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, community ranking, risk and analyst recommendations.
InflaRx has higher earnings, but lower revenue than Affimed. InflaRx is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.
Affimed received 198 more outperform votes than InflaRx when rated by MarketBeat users. Likewise, 69.92% of users gave Affimed an outperform vote while only 64.09% of users gave InflaRx an outperform vote.
In the previous week, InflaRx had 3 more articles in the media than Affimed. MarketBeat recorded 4 mentions for InflaRx and 1 mentions for Affimed. Affimed's average media sentiment score of 1.34 beat InflaRx's score of -0.32 indicating that Affimed is being referred to more favorably in the news media.
InflaRx has a net margin of 0.00% compared to Affimed's net margin of -1,280.27%. InflaRx's return on equity of -40.10% beat Affimed's return on equity.
42.4% of InflaRx shares are held by institutional investors. Comparatively, 30.8% of Affimed shares are held by institutional investors. 16.3% of InflaRx shares are held by insiders. Comparatively, 3.8% of Affimed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
InflaRx has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Affimed has a beta of 2.05, meaning that its share price is 105% more volatile than the S&P 500.
InflaRx presently has a consensus price target of $13.50, indicating a potential upside of 1,025.00%. Affimed has a consensus price target of $45.00, indicating a potential upside of 760.42%. Given InflaRx's stronger consensus rating and higher probable upside, research analysts clearly believe InflaRx is more favorable than Affimed.
Summary
InflaRx beats Affimed on 12 of the 19 factors compared between the two stocks.
Get InflaRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
